Zirgan (ganciclovir 0.15% gel)

Zirgan (ganciclovir 0.15% gel) is filed as Ophthalmic Antiviral. The sections below restate public label fields stored for this profile.

Class
Ophthalmic Antiviral
Generic name
ganciclovir 0.15% gel
Route
OPHTHALMIC
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Ophthalmic gel: 0.15% ganciclovir. Ophthalmic gel: 0.15% ganciclovir. ( 3 )
Manufacturer
Bausch & Lomb Incorporated
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ( 1 )

How it works

12.1 Mechanism of Action ZIRGAN is an antiviral drug [ see Microbiology (12.4) ] .

Boxed warning

WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precautions (5.3) ]. Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans [see Warnings and Precautions (5.4) ]. Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancers in humans [see Warnings and Precautions (5.5) ]. WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS See full prescribing information for complete boxed warning. Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir. ( 5.1 ) Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. ( 5.3 ) Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans. ( 5.4 ) Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancer in humans. ( 5.5 )

Warnings and precautions

BOXED WARNING: WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir [see Warnings and Precautions (5.1) ]. Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females [see Warnings and Precautions (5.3) ]. Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans [see Warnings and Precautions (5.4) ]. Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancers in humans [see Warnings and Precautions (5.5) ]. WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS See full prescribing information for complete boxed warning. Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir. ( 5.1 ) Impairment of Fertility: Based on animal data and limited human data, ganciclovir may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. ( 5.3 ) Fetal Toxicity: Based on animal data, ganciclovir has the potential to cause birth defects in humans. ( 5.4 ) Mutagenesis and Carcinogenesis: Based on animal data, ganciclovir has the potential to cause cancer in humans. ( 5.5 )

Contraindications

4 CONTRAINDICATIONS None. None.

Common side effects

Reported in patients were blurred vision (60%); Eye irritation (20%); Punctate keratitis (5%); And conjunctival hyperemia (5%); Mon adverse reactions were blurred vision (60%)

Dosage and administration

2 DOSAGE AND ADMINISTRATION The recommended dosage is 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days. Apply 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days. ( 2 )

Drug interactions

Drug-drug interaction studies were conducted in patients with normal renal function. Patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug following concomitant administration of Ganciclovir for Injection and drugs excreted by the same pathway as ganciclovir. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug. Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 6 [see Clinical Pharmacology ( 12.3 )] . Table 6. Established and Other Potentially Significant Drug Interactions with Ganciclovir for Injection Name of the Concomitant Drug Change in the Concentration of Ganciclovir or Concomitant Drug Clinical Comment Imipenem-cilastatin Unknown Coadministration with imipenem-cilastatin is not recommended because generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. Cyclosporine or amphotericin B Unknown Monitor renal function when Ganciclovir is coadministered with cyclosporine or amphotericin B because of potential increase in serum creatinine [see Warnings and Precautions ( 5.2 )]. Mycophenolate mofetil (MMF) ↔ Ganciclovir (in patients with normal renal function) ↔ MMF (in patients with normal renal function) Based on increased risk, patients should be monitored for hematological and renal toxicity. Other drugs associated with myelosuppression or nephrotoxicity (e.g., dapsone, doxorubicin, flucytosine, hydroxyurea, pentamidine, tacrolimus, trimethoprim/sulfamethoxazole, vinblastine, vincristine and zidovudine) Unknown Because of potential for higher toxicity, coadministration with Ganciclovir should be considered only if the potential benefits are judged to outweigh the risks. Didanosine ↔ Ganciclovir ↑ Didanosine Patients should be closely monitored for didanosine toxicity (e.g., pancreatitis). Probenecid ↑Ganciclovir Ganciclovir for Injection dose may need to be reduced. Monitor for evidence of ganciclovir toxicity.

Common questions

What is Zirgan approved to treat?

According to its FDA label, Zirgan (ganciclovir 0.15% gel) is approved for: 1 INDICATIONS AND USAGE ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers)… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Zirgan?

Zirgan (ganciclovir 0.15% gel) belongs to the Ophthalmic Antiviral class of medications.

What form does Zirgan come in?

The FDA label lists Zirgan (ganciclovir 0.15% gel) as: 3 DOSAGE FORMS AND STRENGTHS Ophthalmic gel: 0.15% ganciclovir. Ophthalmic gel: 0.15% ganciclovir. ( 3 ); ophthalmic route. Available strengths and packaging vary by manufacturer.

Does Zirgan have a Boxed Warning?

Yes. The FDA label for Zirgan (ganciclovir 0.15% gel) carries a Boxed Warning. Excerpt: "WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS Hematologic Toxicity: Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients tre…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Zirgan cost?

Public CMS NADAC pricing for Zirgan (ganciclovir 0.15% gel) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Zirgan currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Zirgan (ganciclovir 0.15% gel) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Zirgan approved by the FDA?

The FDA record lists the approval date for Zirgan (ganciclovir 0.15% gel) as 2009-09-15.

Who makes Zirgan?

The FDA label lists Bausch & Lomb Incorporated as a labeler/manufacturer of Zirgan (ganciclovir 0.15% gel). Multiple firms may market generics of the same molecule.

How should Zirgan be stored?

The FDA label states: "ZIRGAN (ganciclovir ophthalmic gel) 0.15% is supplied as 5 grams of a sterile, preserved, clear, colorless, topical ophthalmic gel containing 0.15% of ganciclovir in a polycoated aluminum tube with a white polyethylene t…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…